RTP Mobile Logo
Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma
Released December 2013

Roundtable participants include Drs Andrew M Evens, Christopher Flowers, Jonathan W Friedberg, Julie M Vose and Michael E Williams. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative disorders and is one of the most rapidly evolving fields in hematology and oncology. In contrast, Hodgkin lymphoma (HL) is a rarer disease that is relatively chemosensitive and often curable when treated appropriately. However, care for patients who do not respond to primary treatment or for those with relapsed or refractory HL remains a significant challenge for oncology clinicians. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. This program uses a roundtable discussion with leading clinical investigators to assist practicing clinicians in formulating up-to-date clinical management strategies for NHL, HL and chronic lymphocytic leukemia (CLL).

    LEARNING OBJECTIVES

    • Develop an understanding of emerging efficacy and side-effect data with novel agents and combination regimens under evaluation for indolent and aggressive B-cell and T-cell NHL.
    • Incorporate new therapeutic strategies into the best-practice management of HL.
    • Develop an algorithm for the evaluation and treatment of newly diagnosed and relapsed/refractory CLL.
    • Devise an evidence-based approach for the sequential systemic treatment of peripheral T-cell lymphoma.
    • Communicate the existing and emerging roles of proteasome inhibitors and IMiDs to patients with relapsed/refractory mantle-cell lymphoma.
    • Utilize available research evidence and understand the controversies surrounding the use of CNS prophylaxis to guide treatment decision-making for patients with diffuse large B-cell lymphoma.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio MP3s, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/HOUTT113/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr EvensAdvisory Committee: Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc; Contracted Research: Millennium: The Takeda Oncology Company, ZIOPHARM Oncology Inc. Dr FlowersConsulting Agreements: Celgene Corporation, Genentech BioOncology; Contracted Research: Abbott Laboratories, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi, Spectrum Pharmaceuticals Inc. Dr FriedbergAdvisory Committee: Genentech BioOncology; Data and Safety Monitoring Board: Lilly. Dr VoseContracted Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Sanofi, US Biotest Inc. Dr WilliamsAdvisory Committee: Celgene Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pharmacyclics Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Seattle Genetics and Spectrum Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2013
    Expiration date: December 2014

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma
Released December 2013

Roundtable participants include Drs Andrew M Evens, Christopher Flowers, Jonathan W Friedberg, Julie M Vose and Michael E Williams. (Text and Audio Content)

Read print: